Peregrine Capital Management LLC lifted its position in Inari Medical, Inc. (NASDAQ:NARI - Free Report) by 1.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 183,609 shares of the company's stock after purchasing an additional 3,280 shares during the quarter. Peregrine Capital Management LLC owned about 0.31% of Inari Medical worth $9,373,000 as of its most recent SEC filing.
Several other institutional investors have also recently modified their holdings of NARI. R Squared Ltd purchased a new position in shares of Inari Medical in the fourth quarter worth about $45,000. KBC Group NV raised its position in Inari Medical by 39.0% during the third quarter. KBC Group NV now owns 1,774 shares of the company's stock valued at $73,000 after acquiring an additional 498 shares in the last quarter. Covestor Ltd raised its position in Inari Medical by 63.5% during the third quarter. Covestor Ltd now owns 2,384 shares of the company's stock valued at $99,000 after acquiring an additional 926 shares in the last quarter. GAMMA Investing LLC raised its position in Inari Medical by 66.8% during the fourth quarter. GAMMA Investing LLC now owns 1,963 shares of the company's stock valued at $100,000 after acquiring an additional 786 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new position in Inari Medical during the third quarter valued at approximately $128,000. 90.98% of the stock is currently owned by hedge funds and other institutional investors.
Inari Medical Stock Performance
Shares of NASDAQ:NARI traded up $0.04 during trading on Friday, reaching $79.97. The stock had a trading volume of 2,359,000 shares, compared to its average volume of 1,064,604. The business has a fifty day moving average price of $71.49 and a 200-day moving average price of $55.42. The stock has a market cap of $4.68 billion, a PE ratio of -59.24 and a beta of 1.02. Inari Medical, Inc. has a 1-year low of $36.73 and a 1-year high of $79.99.
Wall Street Analyst Weigh In
Several research analysts recently weighed in on NARI shares. Piper Sandler lifted their price target on Inari Medical from $52.00 to $80.00 and gave the company a "neutral" rating in a research report on Tuesday, January 7th. BTIG Research reiterated a "neutral" rating on shares of Inari Medical in a research report on Wednesday, January 8th. Truist Financial lifted their price target on Inari Medical from $50.00 to $63.00 and gave the company a "hold" rating in a research report on Wednesday, December 18th. Oppenheimer started coverage on Inari Medical in a research report on Tuesday, December 17th. They set an "outperform" rating and a $75.00 price target for the company. Finally, Wells Fargo & Company reiterated an "equal weight" rating and set a $80.00 price target (up from $65.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Twelve investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Inari Medical presently has an average rating of "Hold" and a consensus price target of $68.00.
Read Our Latest Stock Report on NARI
Insider Transactions at Inari Medical
In other news, Director William Hoffman sold 200,000 shares of Inari Medical stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $60.47, for a total value of $12,094,000.00. Following the sale, the director now directly owns 238,987 shares of the company's stock, valued at $14,451,543.89. The trade was a 45.56 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Andrew Hykes sold 3,000 shares of Inari Medical stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $55.29, for a total value of $165,870.00. Following the completion of the sale, the chief executive officer now directly owns 439,310 shares in the company, valued at $24,289,449.90. This represents a 0.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 263,000 shares of company stock valued at $15,599,470 over the last ninety days. Insiders own 10.60% of the company's stock.
Inari Medical Company Profile
(
Free Report)
Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.
Further Reading
Before you consider Inari Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inari Medical wasn't on the list.
While Inari Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
